ICSTI Statement on Nanotechnology - Forfás

More documents

Recommendations

Info

As stated, Fab 24 will house Intel's latest process technology, the most advanced semiconductor manufacturing process in the industry. The facility is scheduled for completion and full-scale production in the first half of 2004. This new 90 nm process combines higher-performance, lower-power transistors, strained silicon, high-speed copper interconnects and a new low κ dielectric material. This is the first time all of these technologies will be integrated into a single manufacturing process. Intel's 90 nm process will feature transistors measuring only 50 nm in length (gate length), which will be the smallest, highest performing CMOS transistors in production. By comparison, the most advanced transistors in production today, found in Intel® Pentium® 4 processors, measure 60 nm. Small, fast transistors are the building blocks for very fast processors. These transistors feature gate oxides that are only five atomic layers thick (1.2 nm). A thin gate oxide increases transistor speed. LittleFuse Ireland is based in Dundalk, a subsidiary of LittleFuse Corporation in Chicago, and is a world leader in the design, research and development and production of Transient Suppression Devices. Metal Oxide Varistors were first introduced to the plant in the 1970’s. By the mid 80’s the business focused exclusively on Zinc Oxide Varistors where market demand was rapidly growing. LittleFuse Ireland’s interest in nanoparticle based powders stems from the increased sinter activity of higher specific surface area powders. This can potentially reduce the processing temperatures of varistors leading to the use of cheaper electrode materials and higher voltage devices arising from reduced grain sizes. The company recognises the potential opportunities nanotechnology may provide. In terms of timeframe, they will focus on applying nanotechnology to their existing products and processes to reduce costs and maintain competitive advantage. 63
64 Elan Corporation develops and markets pharmaceuticals and drug-delivery technology. Its pharmaceutical business focuses on neurology, pain management, dermatology, antibiotics, and autoimmune diseases. Its drug delivery business developed and patented the NanoCrystal system for formulating poorly soluble compounds as nanoparticles, thereby increasing their surface area and their solubility. There are currently two pharmaceutical products that have been commercialised incorporating NanoCrystal technology, with several additional product launches anticipated over the next two years. The NanoCrystal technology is protected by 85 issued US patents and 48 pending patents. Elan has established manufacturing scale capability for pharmaceutical products formulated using their proprietary NanoCrystal technology at their Irish development and manufacturing site in Athlone. A drug in nano-form can be incorporated into common dosage forms, including tablets, capsules, inhalation devices, sterile forms for injection, with the potential for substantial improvements to clinical performance. Aerogen Ireland Ltd is a subsidiary of Aerogen Inc based in California, a specialty pharmaceutical company developing inhaled drug products to advance the treatment of respiratory disorders and chronic diseases. The company is focused on efficient, convenient delivery of aerosolised drugs to the lungs, and through the lungs to the blood stream. Its Irish operations are based in Galway where the core business is in the manufacture of pulmonary drug delivery devices. Aerogen’s range of current and future products includes specialised nebulisers and breathactivated inhalers for marketing by Aerogen, as well as novel inhalers for leading pharmaceutical and biotechnology companies. Aerogen have recently established a small three-person team, based in Galway, to formulate drugs as nanoparticles for aerosol delivery. The company has stated that the recent changes to Elan in this country have led to the availability of some highly skilled individuals.
Page 1 and 2:
I C STI I R E L A N D Irish Council
Page 3 and 4:
FUNCTIONS OF THE IRISH COUNCIL FOR
Page 5 and 6:
2 CONTENTS 6.5 Healthcare - Medical
Page 7 and 8:
4 1.0 EXECUTIVE SUMMARY Knowledge e
Page 9 and 10:
6 Nanotechnology - National Roadmap
Page 11 and 12:
8 Assuming that the recommendations
Page 13 and 14:
10 A significant increase in the nu
Page 15 and 16: 12 2.0 INTRODUCTION 2.1 Background
Page 17 and 18: 14 2.5 Acknowledgements The Council
Page 19 and 20: 16 and lowered as it scans across t
Page 21 and 22: 18 Figure 3.3: Nanocrystals of the
Page 23 and 24: 20 4.0 ROADMAP 4.1 Background The n
Page 25 and 26: 22 4.4 Nanotechnology Enabled Produ
Page 27 and 28: 24 5.0 OPPORTUNITY 5.1 Background I
Page 29 and 30: 26 5.3 Improved Products and Proces
Page 31 and 32: 28 Figure 5.2: The launch of vehicl
Page 33 and 34: 30 An example of a multinational co
Page 35 and 36: 32 5.6 Conclusions Based on the abo
Page 37 and 38: 34 The above work for each sector w
Page 39 and 40: 36 Year of Production 2002 2004 200
Page 41 and 42: 38 Ireland should examine its curre
Page 43 and 44: 40 At the present time the photonic
Page 45 and 46: 42 6.4.2 Sector Roadmap From a tech
Page 47 and 48: 44 The growth of the medical device
Page 49 and 50: 46 Table 6.4: Challenges facing the
Page 51 and 52: 48 STAGE ONE: 1980 - 2000 STAGE TWO
Page 53 and 54: 50 it is possible that there will b
Page 55 and 56: 52 6.7.3 Intersection with Nanotech
Page 57 and 58: 54 6.8 Construction Sector 6.8.1 Se
Page 59 and 60: 56 More importantly, nanotechnology
Page 61 and 62: 58 7.0 CAPABILITY 7.1 Background Th
Page 63 and 64: 60 Higher Education Authority; thro
Page 65: 62 Enterprise Ireland is seeking to
Page 69 and 70: 66 There are at least six establish
Page 71 and 72: 68 In respect of the second issue,
Page 73 and 74: 70 9.0 NATIONAL NANOTECHNOLOGY FORU
Page 75 and 76: 72 9.3 Conclusions The immediate es
Page 77 and 78: 74 The co-ordination of the funding
Page 79 and 80: 76 10.4 Conclusions The above strat
Page 81 and 82: 78 APPENDIX II Appendix II: Task Fo
Page 83 and 84: 80 Wednesday, 5th March 2003, Gover
Page 85 and 86: 82 Europe - Commission Nanotechnolo
Page 87 and 88: 84 Another important aspect of fund
Page 89 and 90: 86 Enterprise Ireland has already d
Page 91 and 92: 88 2. What is Nanotechnology? Nanot
Page 93 and 94: 90 For example the application of n
Page 95 and 96: 92 3.1.1 Electronics The electronic
Page 97 and 98: 94 3.2. Market development timescal
Page 99 and 100: 96 There are two start-up nanotechn
Page 101 and 102: 98 4.3 Established EI Clients A num
Page 103 and 104: 100 6. Primary targets for the deve
Page 105 and 106: 102 Objective 3. Increase the numbe
Page 107 and 108: 104 Objective 7. Assist researchers
Page 109 and 110: 106 Potential industrial adopters n
Page 111 and 112: 108 Section 2 - National and Intern
Page 113 and 114: 110 ii. Technology Development Rese
Page 115 and 116: 112 UCD Prof. Donald 961,000 Using
Page 117 and 118:
114 5. European Union Funding via F
Page 119 and 120:
116 UCD HPMD-CT-2000-00014 0.45 Cha
Page 121 and 122:
118 Communications Communications i
Page 123 and 124:
120 (b) SMEs that are inventors of
Page 125 and 126:
122 Dr. Pat Morgan Dean, Faculty of
Page 127 and 128:
124 A Partnership Approach to Resea
Page 129:
July 2004
show all

ICSTI Statement on Nanotechnology - Forfás

Create successful ePaper yourself

Delete template?

Save as template?